Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Novartis gets approval to sell Kymriah in Japan for $306,000

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 04:29am EDT
FILE PHOTO: FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel

TOKYO (Reuters) - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis' cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.

The one-time, personalised therapy, which was approved in Japan in March, will be available in the country for young people with acute lymphoblastic leukaemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

The so-called CAR-T therapy, which Novartis believes could treat up to 216 Japanese patients a year, potentially generating annual sales of 7.2 billion yen ($65.7 million), has been a hailed as a revolutionary, last-ditch hope for people whose cancer advanced after previous treatment.

But the Basel-based drugmaker has faced U.S. hurdles, largely for DLBCL patients, where challenges meeting commercial specifications have forced it to give some product away for free. Expanding to Japan, plus ongoing efforts to resolve the U.S. problems, are part of Chief Executive Vas Narasimhan's goal of turning Kymriah into $1 billion-per-year seller.

The U.S. specification hiccup is not an issue in Japan, a spokesman said.

"Our cell viability commercial specifications in the EU, Switzerland, Australia, Canada and Japan are now aligned with those from our clinical trials," the spokesman said. "We intend to continue to engage with the (U.S. Food and Drug Administration) to change our commercial viability specifications in the United States."

While the impasse has been a "disappointment," Novartis added its scientists had recorded comparable safety and efficacy even with Kymriah that doesn't meet FDA specifications.

"We continue to optimize our process and make incremental gains as we work toward our ultimate goal of providing this transformative product to patients in both indications, and have been able to deliver Kymriah to the majority of patients," the company said.

Kymriah works by removing disease fighting T-cells from patients, modifying them to attack cancer, and re-infusing them back into the patients.

The therapy belongs to a slate of advanced, costly therapies including gene therapy and cancer-fighting nuclear medicine that Narasimhan has either developed or bought via acquisitions as he maps out Novartis's future.

For U.S. patients, Kymriah costs $475,000 for those with ALL and $373,000 for DLBCL.

Global sales of Kymriah were $76 million in 2018, putting it well outside Novartis's top 20 medications. It's also shy of Gilead Sciences' Yescarta, another CAR-T therapy that last year posted $264 million in sales but which also missed analyst expectations.

(Reporting by Takashi Umekawa; Additional reporting by John Miller in Zurich; Editing by Muralikumar Anantharaman and Mark Potter)

By Takashi Umekawa

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 1.61% 69.93 Delayed Quote.10.06%
NOVARTIS 0.90% 91.05 Delayed Quote.21.44%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08:39aGILEAD SCIENCES : Singapore Health Sciences Authority Approves Vosevi(R) (Sofosb..
AQ
06/24GILEAD SCIENCES : and Carna Biosciences Announce Research and Development Collab..
BU
06/23GILEAD SCIENCES : US company launches campaign during Africa Cup to eliminate He..
AQ
06/20GILEAD SCIENCES : With $45M Nurix Deal, Gilead Enters Crowded Protein Degradatio..
AQ
06/20GILEAD SCIENCES : and Nurix Establish Strategic Collaboration to Develop Novel T..
AQ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/19GILEAD SCIENCES : and Nurix Establish Strategic Collaboration to Develop Novel T..
BU
06/17GILEAD SCIENCES : A new era for Gilead
AQ
06/14GILEAD SCIENCES : A cure for HIV? Gilead VP in Israel for Pride Parade says one ..
AQ
06/14GILEAD SCIENCES : AbCellera Announces Therapeutic Antibody Discovery Collaborati..
AQ
More news
Financials ($)
Sales 2019 22 048 M
EBIT 2019 11 439 M
Net income 2019 6 954 M
Debt 2019 5 962 M
Yield 2019 3,67%
P/E ratio 2019 12,66
P/E ratio 2020 12,50
EV / Sales 2019 4,24x
EV / Sales 2020 3,86x
Capitalization 87 534 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,0 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.06%80 909
VERTEX PHARMACEUTICALS9.24%42 680
REGENERON PHARMACEUTICALS-16.32%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC16.69%8 523
NEUROCRINE BIOSCIENCES, INC.18.33%7 500